aurobindo - national stock exchange of india...aurobindo pharma limited disclosure ofrelaled party...

December 3,2019

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI·400 051

Company Code No. AUROPHARMA

Dear Sirs,

AUROBINDO

To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI·400 001

Company Code No. 524804

Sub: Disclosure of Related Party Transactions for the half year ended 30th September 2019. Ref: Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure

Requirements) Regulations, 2015.

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended 30th September 2019.

Please take the information on record .

Thanking you,

Yours faithfully, For AUROBINDO PHARMA LIMITED

~,\L,~ B Adi Reddy Company Secretary

Encl: as above.

(GIN: L24239TG 1986PLG0151901 AUROBINDO PHARMA LIMITED

PAN No. AABGA7366H

Corp off.: The Water Mark Building, Plot No.11. Survey No.9, Hi·tech City, Kondapur, Hyderabad· 500 084 IS., INDIA Tel: +91 406672 5000 /1200 Fax: +91 4067074059

Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad· 500 038 IS., INDIA Tel: +91 4023736370 Fax : +91 4023747340, Email : info@aurobindo.com

www.aurobindo.com

Auroblndo Pharma Limited Disclosure or related party transactions on a consolidated basis for the half year ended 30 September 2019 (All amounts are in Indian Rupees in millions)

i) Names of related pftrties and description of relationship

a) Joint ventures Novagen Phanna (Pty) Limited. South Africa (Joint Venture ofa step-down subsidiary. Aurogen South Africa (Pty) Ltd. South Africa) Eugia Pharma Specialities Limited. India (Joint Venture ofa step-down subsidiary. Curepro parenterals Ltd) Tergene Biotech Private Limited, India Raidurgam Developers Limited. India (formerly known as Aurobindo Antibiotics limited. India) Purple Bellflower (Pty)Ltd. South Africa (Joint Venture ofa step-down subsidiary. Aurogen South Africa (Pty) Ltd, South Africa) Luoxin Aurovitas Phann (Chengdu) Co Ltd (Joint Venture ofa step-down subsidiary. Helix Healthcare B V)

b) Enterprises over which key management personnel or their relatives exercise signiricant influence Pravesha Industries Private Limited, India Sri Sai Packaging. India (Partnership firm) Trident Chemphar Limited. India Axis Clinicals Limited. India Pranit Packaging Private Limited, India SGD Pharma India Limited (formerly Cogent Glass Limited). India Orem Access BiD Inc, India Veritoz Healthcare Limited. India Axis Clinicals LLC. USA Crest Cellulose Private Limited, India East Phanna Technologies. India (Partnership firm) Axis Clinicals Latina SA DE CV. Mexico Gelcaps Industries. India Aurobindo Foundation, India Giyaan Phanna Private Limited. India Alcedo Pharmachem Private Limited, India Ambipack Industries. India

c) Key managerial personnel Mr K. Nityananda Reddy. Whole-time Director Dr M Sivakumaran, Whole-time Director Mr M Madan Mohan Reddy. Whole-time Director Mr P Sarath Chandra Reddy. Whole-time Director Mr N Govindarajan. Managing Director Mr Santhanam Subramanian, Chief Financial Officer Mr B. Adi Reddy. Company Secretary Mr K Ragunathan, Non-executive Chairman and Independent Director Mr. M. Sitarama Murty. Independent Director Dr (Mrs) Avnit Bimal Singh. Independent Director Mr P.Venkata Rarnprasad Reddy, Non Executive promoter director Mrs Savitha Mahajan, Independent Director

d) Relatives to key managerial personnel Mr Vishnu M Sri ram (Son in law of Dr M Sivakumaran. Wholetime Director)

II) Transactions with related parties a. Transactions with joint ventures

Raidurgam Developers Limited Investment in optionally convertible debentures Interest accrued

Novagen Pharma (Ply) Limited, South Africa Sale of products Sale of services Dividend received

E_gia Ph.rma Specialities Ltd, India Sale of products Purchases

Tergene Biotech Pvt. Ltd, India Investment in 105% Cumulative Redeemable Preference shares

H.lrVe.r ended 30 September 2019

64.0 12.2

92.3 17.7 24.0

60.0 1,368.1

14.0

Aurobindo Pharma Limited Disclosure ofrelaled party transactions on ft consolidated basis for the half year ended 30 September 2019 (All amounts are in Indian Rupees in millions)

b. Tranuctions with cll luprht'.I' over whi~h key lUilnJlgcm~.n 1 prt'!ollnd or their relatives exercis.e significant in.Onen«

Pravesha Industries Private Limited, India Purchases Sri Sai Packaging, India Sale of products Purchases Axis Clinicals Limited, India Purchase of services Purchase afFixed assets Axis Clinicals LLC, USA Purchase of services Purchase afFixed Assets Axis Clinicals Latina SA DE CV, Mexico 11urdmR. of servlcc.t Trident Chemphar Limited, India Purchases Purchase of services Pranit Packaging Private Limited, India Purchases SGD Pharma India Limited (formerly Cogent Gla .. Limited), Indio Purchases Purchase of services Orem Access Bio Inc, India Purchases Veritaz Healthcare Limited, India Sale of products Rent received Crest Cellulose Private limited, India Purchases East PharmA Techonologies, India Purchases Geltftps Industries, India Purchases Aurobindo Foundation, IndiA Contribution towards CSR activities Giyaan Pharma Private Limited, India Sale of products Alcedo Pharmachem Private Limited, India Purchases Ambipack Industries, India Purchases

c. Transactions with key m8.llftgerial PCJ'!olulel or their relAtives

Mr. K Nityanand. Reddy Managerial remuneration Rent expense Dr. M Sivakumaran Managerial remuneration Mr. M M.dan Mohan Reddy Managerial remuneration Mr. P Saroth Chandra Reddy Managerial remuneration Mr. Vishnu M Sriram Remuneration Mr.N Govindarajan Managerial Remuneration Mr.Santhanam Subramanian Remuneration Mr.B. Adi Reddy Remuneration Mr. P.Venkal. Ramapra •• d Reddy Director sitting fees Mr. K.Ragunathan, Non-executive Chairman and Independent Director Director sitling fees Mr. M. Sitaramft Murty, Independent Director Director sitting fees Mrs.Avnit Bimal Singh, Independent Director Director sitting fees Mrs.SAvithft MahajAn, Independent Director Director sitting fees

Note:

H.lfYear ended 30 September 2019

1,684.7

0.2 120.3

883.6 70.9

55.4 20.7

0.8

616.8 62.9

123.5

633.4 0.3

170.0

1\3.5 0.2

253.5

46.7

212.6

200.0

5.2

95.0

54.3

Half Year ended 30 September 2019

6,8 1.4

6.8

18.4

3.9

3.0

31.4

9.6

2.1

0.2

0.5

0.3

0.4

0.3

Managerial remuneration does not include provision for gratuity and leave encashment, which is determined for the Company as 8 whole

Aurobindo Pharma Limited Disclosure of related party transactions on a consolidated basis for the half year ended 30 September 2019 (AU amounts are in Indian Rupees in millions)

iii) Closing balances or related parties a. Balances with Joint ventures at the year end

Novagen Pharma (Ply) Limited. South Africa Balance receivable

Eugla Pharma Specialities Limited. India Balance receivable Balance payable

As at 30 September 2019

71.4

45.9 944.9

b. Ulllnnc ..... with ~"-terprl"t 0 e.r'~hleh key m.ana.gem.tDt pers.ounel or the.ir relatives tae.I'CiJ~ J.igniOCAnt Innuence at tbe year end.

Pravesha Industries Private Limited, India Balance payable Sri Sai Packaging, India Balance payable Axis Clinicals Limited, India Balance payable Axis Clinica1s LLC. USA Balance receivable Trident Chemphar Limited, India Balance payable

Pta nit Packaging Private Limited. India Balance receivable Balance payable

SGD Pharma India Limited (formerly Cogent Glass Limited). Indi. Balance payable Veritaz Healthcare Limited, India Balance receivable Orem Access Bio Inc, India Balance payable Crest Cellulose Private Limited. India Balance payable

EastPharma Technologies, India Balance payable

Gelcaps Industries. India Balance receivable Balance payable

Giyftan Pharma Private Limited, India Balance receivable AI<edo Pharmachem Private Limited. India Balance payable Ambipack Industries, India Balance payable

c. BalancfJ with with key manREerial personnel at the year end

Mr. K Nilyananda Reddy Balance payable

As at 30 September 2019

982.0

25.5

216.6

2.6

74.3

0.8 27.2

355.5

87.4

80.1

68.2

15.2

1.7 89.0

3.3

65.3

17.5

As at 30 September 2019

0.2